Trial Profile
A Randomized, Double-Blind, Active-Controlled Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk and Not Adequately Controlled With Atorvastatin: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin Versus Doubling the Baseline Dose of Atorvastatin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 08 Oct 2010 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.